Osteros Biomedica

Osteros Biomedica is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncological diseases affecting bone tissue. The company's primary focus is on its lead candidate, MBC-11, a bone-targeted conjugate designed to treat bone metastases and multiple myeloma. By utilizing a bisphosphonate-based targeting mechanism, the therapy delivers cytotoxic agents directly to the bone microenvironment. This approach aims to concentrate the drug's effect where it is needed most, thereby reducing systemic side effects and improving patient outcomes. Founded as part of the Maxwell Biotech Venture Fund portfolio, the company has received significant support from the Skolkovo Foundation.